{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T01:25:57Z","timestamp":1785288357893,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004097","name":"ARC Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ejca.2025.115534","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:30:55Z","timestamp":1748979055000},"page":"115534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Predictive value of BRCA1\/RAD51C methylation in HGSOC \u2013 An ancillary study of the PAOLA-1\/ENGOT-ov25 phase 3 trial"],"prefix":"10.1016","volume":"225","author":[{"given":"H.","family":"Blons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Abdelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Landman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Taly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mulot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Laurent-Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Harter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Polterauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hietanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"De La Motte Rouge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Buderath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.C.","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bataillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pujade-Lauraine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115534_bib1","first-page":"209","article-title":"Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2025.115534_bib2","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115534_bib3","first-page":"681","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the paola-1\/engot-ov25 trial. ann. oncol. off. j. eur. soc","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Med Oncol"},{"key":"10.1016\/j.ejca.2025.115534_bib4","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115534_bib5","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115534_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100144","article-title":"The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?","volume":"6","author":"Ngoi","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2025.115534_bib7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO\u2013ESMO\u2013ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115534_bib8","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.annonc.2021.11.013","article-title":"European experts consensus: BRCA\/homologous recombination deficiency testing in first-line ovarian cancer","volume":"33","author":"Vergote","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115534_bib9","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115534_bib10","doi-asserted-by":"crossref","unstructured":"Guarischi-Sousa, R. et al. HRD-One: CLINICAL VALIDATION AND PERFORMANCE ASSESSMENT. Comparison between Myriad\u2019s myChoice\u00ae, SOPHiA GENETICS\u00ae SOPHiA Homologous Recombination Solution and AmoyDx\u00ae HRD Focus Panel. Preprint at https:\/\/doi.org\/10.1101\/2023.03.28.21264560 (2023).","DOI":"10.1101\/2023.03.28.21264560"},{"key":"10.1016\/j.ejca.2025.115534_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114127","article-title":"Harmonization of homologous recombination deficiency testing in ovarian cancer: results from the MITO16A\/MaNGO-OV2 trial","volume":"206","author":"Roma","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115534_bib12","article-title":"Homologous recombination repair gene mutations to predict olaparib plus bevacizumab efficacy in the first-line ovarian cancer PAOLA-1\/ENGOT-ov25 trial. jco precis","volume":"7","author":"Pujade-Lauraine","year":"2023","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2025.115534_bib13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2025.115534_bib14","doi-asserted-by":"crossref","first-page":"8837","DOI":"10.1074\/jbc.274.13.8837","article-title":"Positive regulation of the BRCA1 promoter","volume":"274","author":"Thakur","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2025.115534_bib15","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/jnci\/djaa070","article-title":"BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis","volume":"112","author":"Kalachand","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2025.115534_bib16","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/0008-5472.CAN-07-2418","article-title":"Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer","volume":"68","author":"Potapova","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2025.115534_bib17","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/cbt.5.3.2380","article-title":"Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting fanconi anemia-BRCA pathway","volume":"5","author":"Wang","year":"2006","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ejca.2025.115534_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcae033","article-title":"High-level tumour methylation of BRCA1 and RAD51C is required for homologous recombination deficiency in solid cancers","volume":"6","author":"Xu","year":"2024","journal-title":"NAR Cancer"},{"key":"10.1016\/j.ejca.2025.115534_bib19","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1158\/1078-0432.CCR-23-0563","article-title":"Assessment of homologous recombination deficiency in ovarian cancer","volume":"29","author":"Garg","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.115534_bib20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jmoldx.2023.01.003","article-title":"Pyrosequencing assay for BRCA1 methylation analysis","volume":"25","author":"Sahnane","year":"2023","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ejca.2025.115534_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jmoldx.2024.11.004","article-title":"Validation and performance of quantitative BRCA1 and RAD51C promoter hypermethylation testing in breast and ovarian cancers","volume":"27","author":"Fink","year":"2025","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ejca.2025.115534_bib22","doi-asserted-by":"crossref","first-page":"9708","DOI":"10.3390\/ijms21249708","article-title":"BRCA methylation testing identifies a subset of ovarian carcinomas without germline variants that can benefit from PARP inhibitor","volume":"21","author":"Sahnane","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2025.115534_bib23","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1158\/1078-0432.CCR-18-0179","article-title":"BRCA1 promoter methylation is linked to defective homologous recombination repair and elevated miR-155 to disrupt myeloid differentiation in myeloid malignancies","volume":"25","author":"Poh","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.115534_bib24","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1158\/1078-0432.CCR-22-3328","article-title":"Clinical relevance of BRCA1 promoter methylation testing in patients with ovarian cancer","volume":"29","author":"Blanc-Durand","year":"2023","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2025.115534_bib25","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1038\/s41467-021-22582-6","article-title":"Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)","volume":"12","author":"Swisher","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2025.115534_bib26","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1038\/s41467-018-05564-z","article-title":"Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma","volume":"9","author":"Kondrashova","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2025.115534_bib27","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","article-title":"Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors","volume":"92","author":"Esteller","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2025.115534_bib28","doi-asserted-by":"crossref","unstructured":"Nesic, K. et al. Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma. Preprint at https:\/\/doi.org\/10.1101\/2020.12.10.419176 (2020).","DOI":"10.1158\/0008-5472.CAN-21-0774"},{"key":"10.1016\/j.ejca.2025.115534_bib29","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcab028","article-title":"Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance","volume":"3","author":"Hurley","year":"2021","journal-title":"NAR Cancer"},{"key":"10.1016\/j.ejca.2025.115534_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00258","article-title":"Homologous recombination repair gene mutations to predict olaparib plus bevacizumab efficacy in the First-Line ovarian cancer PAOLA-1\/ENGOT-ov25 trial","author":"Pujade-Lauraine","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2025.115534_bib31","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.4161\/epi.22561","article-title":"BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer","volume":"7","author":"Stefansson","year":"2012","journal-title":"Epigenetics"},{"key":"10.1016\/j.ejca.2025.115534_bib32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ygyno.2005.10.034","article-title":"BRCA1 promoter methylation predicts adverse ovarian cancer prognosis","volume":"101","author":"Chiang","year":"2006","journal-title":"Gynecol Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925003168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925003168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:36:10Z","timestamp":1762342570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925003168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":32,"alternative-id":["S0959804925003168"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115534","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive value of BRCA1\/RAD51C methylation in HGSOC \u2013 An ancillary study of the PAOLA-1\/ENGOT-ov25 phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115534"}}